CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Bacillus subtilisbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05057923
NCT05057923N/ACompleted
CompareCT.gov

The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores Expressing and Displaying the Receptor Binding Domain of Spike Protein of SARS-COV2

DreamTec Research Limited·interventional·Posted Sep 27, 2021·Updated May 31, 2023

In Brief

A clinical study evaluating Bacillus subtilis for COVID-19 Pneumonia. Completed, enrolled 9 participants across 1 site.

Detailed Summary

This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Pneumonia
CountriesHong Kong
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedSep 27, 2021
Enrollment StartJul 10, 2021
Primary CompletionOct 20, 2021
Study CompletionNov 1, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.8 years ago

Interventions

Bacillus subtilisbiological

Bacillus subtilis, a harmless intestinal commensal, has earned in recent years, great reputation as a vaccine production host and delivery vector with advantages such as low cost, safe for human consumption and straightforward administration. The technology team has succeeded engineering Bacillus subtilis with spore coat proteins resembling the proteins of the nucleus and spikes of coronal virus. This product could have a vaccine like activity within the intestinal environment.